Feasibility of application of an absorbable topical collagen hemostat sheet (INTEGRAN ® ) for prevention of postoperative recurrence of pneumothorax in youths
Staple-line coverage is an effective method for prevention of postoperative recurrence of pneumothorax. However, the recurrence rate in young patients is still unsatisfactory using this method. Moreover, there is no consensus about the optimal material for use in this technique. To explore new mater...
Gespeichert in:
Veröffentlicht in: | Journal of thoracic disease 2021-07, Vol.13 (7), p.3979-3987 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Staple-line coverage is an effective method for prevention of postoperative recurrence of pneumothorax. However, the recurrence rate in young patients is still unsatisfactory using this method. Moreover, there is no consensus about the optimal material for use in this technique. To explore new material for this technique, we conducted this study to evaluate the safety of an absorbable topical collagen hemostat (INTEGRAN
) for staple-line coverage in pneumothorax surgery in young patients.
A single-arm prospective interventional study was performed in 25 patients (age 18,000/mm
and/or CRP >15 mg/dL, or acute empyema within 30 postoperative days) was defined as the primary endpoint. The 1-year postoperative rates of recurrence and of new bullae around the staple-line were also measured.
The median age was 19 years old. None of the patients had a body temperature ≥38 ℃ continuing for ≥2 days, extra-abnormal examination data, and acute empyema findings. At 1-year postoperatively, the recurrence rate was 12.0%, and the rate of new bullae around the staple-line was 16.7%.
This study showed the safety of use of INTEGRAN
for staple-line coverage in pneumothorax surgery in young adults. The short-term recurrence rate was acceptable given the high-risk cohort examined in the study. A prospective randomized controlled study is needed for evaluation of the efficacy of INTEGRAN
for prevention of recurrence of PSP.
UMIN000026530 at UMIN Clinical Trials Registry. |
---|---|
ISSN: | 2072-1439 2077-6624 |
DOI: | 10.21037/jtd-21-274 |